Global private equity firm Carlyle said on Wednesday it led a $312 million funding round for Japanese biotech company Spiber Inc, joining other global investors in betting on a growing number of late-stage Japanese startup firms.
Carlyle’s 10 billion yen ($91 million) stake in Spiber represents the group’s first non-buyout, minority investment in an unlisted startup in Japan, where startup funding is soaring.
The round, which also includes investments from fund managers Fidelity and Baillie Gifford, will be made through a combination of the allotment of new shares and a capital infusion at a valuation of about 135 billion yen ($1.22 billion).
Spiber makes plant-based protein polymers through microbial fermentation, which can be spun into animal- and plastic-free fibres for clothing, auto parts and other uses.
Source: Reuters
By Makiko Yamazaki and Yuki Nitta
Can't stop reading? This and all news articles are property of their creators, many are not owned or provided by Private Equity Insider. As an event organizer and community platform, we curate content from reliable sources for your suggested reading, and advise you to read the full articles from the referenced authors and sources.